Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) SHH
12.59
-0.29(-2.25%)
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
12.59
-0.29(-2.25%)
Currency In CNY
Sector
Healthcare
Industry
Biotechnology
Employees
565
First IPO Date
December 19, 2019
| Name | Title | Pay | Year Born |
| Hao Xiong | Accounting Supervisor | 0 | N/A |
| Xiangyu Li | Deputy General Manager | 0 | 1978 |
| Zhi Bo Li | Deputy General Manager | 0 | 1973 |
| Dewei Yi | Chairman & GM | 0 | 1965 |
| Huabiao Wang | Financial Director & Director | 0 | 1965 |
| Huarong Yi | Deputy GM & Secretary of the Board of Directors | 0 | 1976 |
| Anfeng Geng | Deputy General Manager | 0 | 1976 |
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.